Vanguard Group Inc. Boosts Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Vanguard Group Inc. lifted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 0.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,690,159 shares of the company's stock after purchasing an additional 8,128 shares during the quarter. Vanguard Group Inc. owned about 11.52% of Prestige Consumer Healthcare worth $444,345,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Allspring Global Investments Holdings LLC lifted its holdings in Prestige Consumer Healthcare by 3.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company's stock worth $126,274,000 after buying an additional 49,331 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Prestige Consumer Healthcare by 4.0% in the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock valued at $95,678,000 after purchasing an additional 50,961 shares during the period. Congress Asset Management Co. boosted its holdings in Prestige Consumer Healthcare by 5.0% in the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company's stock valued at $70,964,000 after purchasing an additional 43,619 shares during the period. Boston Trust Walden Corp grew its stake in Prestige Consumer Healthcare by 43.5% during the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock worth $64,942,000 after purchasing an additional 252,089 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Prestige Consumer Healthcare by 5.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company's stock worth $49,667,000 after purchasing an additional 33,844 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Remove Ads

Prestige Consumer Healthcare Stock Performance

NYSE:PBH traded down $1.70 during trading hours on Friday, reaching $82.85. 568,886 shares of the company's stock were exchanged, compared to its average volume of 277,459. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $4.10 billion, a price-to-earnings ratio of 19.40, a P/E/G ratio of 2.69 and a beta of 0.46. The company has a 50-day moving average of $84.03 and a 200 day moving average of $79.48.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Oppenheimer boosted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Finally, Royal Bank of Canada raised their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a report on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.